JP2021519069A5 - - Google Patents

Info

Publication number
JP2021519069A5
JP2021519069A5 JP2020551499A JP2020551499A JP2021519069A5 JP 2021519069 A5 JP2021519069 A5 JP 2021519069A5 JP 2020551499 A JP2020551499 A JP 2020551499A JP 2020551499 A JP2020551499 A JP 2020551499A JP 2021519069 A5 JP2021519069 A5 JP 2021519069A5
Authority
JP
Japan
Prior art keywords
cells
hiv
pbmc
subset
pbmcs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519069A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024410 external-priority patent/WO2019191314A1/en
Publication of JP2021519069A publication Critical patent/JP2021519069A/ja
Publication of JP2021519069A5 publication Critical patent/JP2021519069A5/ja
Priority to JP2024046892A priority Critical patent/JP2024073653A/ja
Pending legal-status Critical Current

Links

JP2020551499A 2018-03-27 2019-03-27 遺伝子改変リンパ球の製造方法 Pending JP2021519069A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024046892A JP2024073653A (ja) 2018-03-27 2024-03-22 遺伝子改変リンパ球の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648804P 2018-03-27 2018-03-27
US62/648,804 2018-03-27
PCT/US2019/024410 WO2019191314A1 (en) 2018-03-27 2019-03-27 Methods of manufacturing genetically-modified lymphocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024046892A Division JP2024073653A (ja) 2018-03-27 2024-03-22 遺伝子改変リンパ球の製造方法

Publications (2)

Publication Number Publication Date
JP2021519069A JP2021519069A (ja) 2021-08-10
JP2021519069A5 true JP2021519069A5 (cg-RX-API-DMAC7.html) 2022-04-04

Family

ID=68058501

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020551499A Pending JP2021519069A (ja) 2018-03-27 2019-03-27 遺伝子改変リンパ球の製造方法
JP2024046892A Pending JP2024073653A (ja) 2018-03-27 2024-03-22 遺伝子改変リンパ球の製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024046892A Pending JP2024073653A (ja) 2018-03-27 2024-03-22 遺伝子改変リンパ球の製造方法

Country Status (5)

Country Link
US (2) US20210015868A1 (cg-RX-API-DMAC7.html)
EP (1) EP3773622A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021519069A (cg-RX-API-DMAC7.html)
KR (1) KR20200135852A (cg-RX-API-DMAC7.html)
WO (1) WO2019191314A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7153332B2 (ja) 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
CA3028982A1 (en) 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
EP3773622A4 (en) * 2018-03-27 2021-12-01 American Gene Technologies International Inc. METHODS OF PREPARING GENETICALLY MODIFIED LYMPHOCYTES
CA3144413A1 (en) * 2019-07-17 2021-01-21 Rafick-Pierre Sekaly Long lived t cells for treating hiv infection
AU2021232603A1 (en) * 2020-03-03 2022-10-20 American Gene Technologies International Inc. On demand expression of exogenous factors in lymphocytes to treat HIV

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL292038B2 (en) * 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
US10968451B2 (en) * 2014-10-14 2021-04-06 Texas Tech University System Multiplexed shRNAs and uses thereof
GB201509202D0 (en) * 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
US11980663B2 (en) * 2015-07-08 2024-05-14 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
JP7153332B2 (ja) * 2016-02-08 2022-10-14 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivワクチン接種および免疫療法
CA3028982A1 (en) * 2016-07-08 2018-01-11 American Gene Technologies International Inc. Hiv pre-immunization and immunotherapy
US10772887B2 (en) * 2016-08-03 2020-09-15 Kagoshima University Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
EP3773622A4 (en) * 2018-03-27 2021-12-01 American Gene Technologies International Inc. METHODS OF PREPARING GENETICALLY MODIFIED LYMPHOCYTES

Similar Documents

Publication Publication Date Title
US20240091339A1 (en) Pre-immunization and immunotherapy
US20240252615A1 (en) Pre-immunization and immunotherapy
Del Prete et al. Comparative characterization of transfection-and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies
US10888613B2 (en) Method of producing cells resistant to HIV infection
JP2025098175A (ja) 事前の免疫化ステップのないhiv免疫療法
JP2019527055A5 (cg-RX-API-DMAC7.html)
US20240115604A1 (en) Methods of manufacturing genetically-modified lymphocytes
Olbrich et al. Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs
Liu et al. CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals
WO2021178571A1 (en) On demand expression of exogenous factors in lymphocytes to treat hiv
RU2465324C1 (ru) Способ генерации специфического иммунного ответа против антигенов вируса иммунодефицита человека
WO2025050047A1 (en) Combination immunotherapy and antiviral treatment
WO2025064901A2 (en) Hiv vaccination and immunotherapy
Pike The role of CD4+ T cells in Friend virus infection